Format

Send to

Choose Destination
J Health Care Poor Underserved. 2013 Feb;24(1 Suppl):104-11. doi: 10.1353/hpu.2013.0047.

In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models.

Author information

1
Division of Basic Pharmaceutical Sciences, Xavier University of Louisiana, School of Pharmacy, 1 Drexel Drive, New Orleans, LA 70125, USA. kparker1@xula.edu

Abstract

Triple negative breast cancer (TNBC) is subtype of breast disease devoid of the estrogen, progesterone, and Her2/neu receptors which are targets for pharmacological intervention. There is a need for novel anti-breast cancer agents that target TNBC. Therefore, novel isochalcone DJ52 was evaluated using the alamar blue dye exclusion assay, the luciferase colony assay, and xenograft models to determine its efficacy and potency. DJ52 significantly decreased proliferation of cells measured by using the alamar blue dye method and produced IC50 values of DJ52, DJ56, and DJ82 at 10-6M, 10-5M, and 10-5M, respectively. In vivo studies were conducted by injecting MDA-MB-231 cells into SCID mice to determine tumor regression was measured over 20 days. DJ52 at 50 mg/kg caused significant decrease in tumor volume (p value <.05) by nearly 50% compared with the control with vehicle alone. These data suggest that DJ52 has merit for further evaluation as a novel anticancer agent.

PMID:
23395947
PMCID:
PMC3628744
DOI:
10.1353/hpu.2013.0047
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Project MUSE Icon for PubMed Central
Loading ...
Support Center